- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Antibody Production
- Protein Production
- Protein Characterization
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
Poster modified on 17/10/2023
Accelerating Early Drug Discovery Process with Vanilla Antibody Production using 777 Platform
Gaozhan Zhang, Deyang Zeng, Dawei Zhang, Mengjie Lu, Jiansheng Wu
WuXi Biologics, NO.240 Hedan Road, Pudong New District, Shanghai, China
The assessment of binding affinity, biological properties, and critical developability parameters for thousands of candidates in early antibody drug discovery process often requires small amounts of purified materials (< 1g). To support our clients and to overcome the challenges associates with protein production, WuXi Biologics has established one HTP antibody production platform “777”, representing 7 days for gene synthesis, 7 days for protein expression, and 7 days for purification and QC.
This scientific poster was originally presented during the 2023 World ADC Conference in London
Discuss This Poster
To discuss the data in this poster, please complete the form on the following page to connect with our experts.